To clarify, 2QFY2025 = 4Q2024 = Oct ~ Dec 2024 = quarter ending December 2024 . (For the newcomers)."NYR-BI03 is currently undergoing GLP safety and tolerability studies ahead of a first-in-human Phase I clinical trial expected to commence in the quarter ending December 2024.Thus far, six out of nine GLP studies have been completed.Subject to satisfactory completion of this Phase I trial, NYR-BI03 has the potential to progress directly to Phase II trials to assess its efficacy in the following" '3' treatment Markets:1. Stroke2. Traumatic brain injury, and now3. Myocardial ischemia-reperfusion injury.Regarding 3. above, (todays announcement content), currently, "it is a great challenge in the therapy of cardiovascular disease and a common clinical complication".Current treatment includes Captopril or Capoten, an FDA-approved ACE inhibitor commonly administered following ischhttps://www.sciencedirect.com/science/article/pii/S001948321630236Xemic events and used in this study as a positive control. Captopril is owned by Global BioPharma co. Bristol-Myers Squibb...https://fintel.io/so/us/bmy
NYR-BIO3 will benefit many humans across the globe if successful.
This is not advice nor is it an intended bias. Please, DYOR.
To clarify, 2QFY2025 = 4Q2024 = Oct ~ Dec 2024 = quarter ending...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.040(61.5%) |
Mkt cap ! $19.13M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 14.5¢ | 9.2¢ | $1.422M | 12.21M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 42093 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30678 | 3 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| NYR (ASX) Chart |